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The new drugs developed for the treatment of anemia in chronic kidney disease patients,
together with their mechanisms of action are reviewed. At present, many of them are already
in  advanced stages of clinical trials and is expected to be incorporated into the therapeu-
tic  arsenal in the coming years. The potential beneﬁts and possible limitations are also
described.
©  2016 Sociedad Espan˜ola de Nefrologı´a. Published by Elsevier Espan˜a, S.L.U. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Nuevas  expectativas  en  el  tratamiento  de  la  anemia  en  la  enfermedad
renal  crónica
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Se revisan los nuevos fármacos desarrollados para el tratamiento de la anemia en la enfer-
medad renal crónica, junto con sus mecanismos de acción. En la actualidad, muchos de
ellos se encuentran ya en fases avanzadas de ensayos clínicos y es de esperar que se incor-
Inhibidores de prolil-hidroxilasa
Sotatercept
Hepcidina
poren al arsenal terapéutico en los próximos an˜os. Se describen las potenciales ventajas y
sus  posibles limitaciones.
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naemia is a common complication in advanced chronic
idney disease (ACKD) and its severity increases as kid-
ey function decreases. The introduction of treatment with
ecombinant human erythropoietin (EPO) (epoetin) three
ecades ago entirely changed the magnitude of the problem.1
able 1 shows the most important events in the treatment of
his condition to date.1–7 Throughout this time, the treatment
f anaemia has been based on the use of erythropoiesis-
timulating agents (ESAs), which included epoetin and its
nalogues, together with the administration of iron by oral
r parenteral route.8 The analogues of erythropoietin include
arbepoetin and CERA (continuous erythropoietin receptor
ctivator). Darbepoetin is composed of an EPO that includes
wo sialic acid molecules, giving it a longer half-life, while
ERA is a pegylated EPO, with an even greater half-life. In
ecent years, agents that are biosimilar to epoetin have been
ncorporated into the therapeutic arsenal, as they are less
xpensive.
The objective of this review is to raise awareness of the
rugs that are currently in different clinical trial phases and
hat may constitute the basis of treatment for renal anaemia
n the coming years. Table 2 shows a simple classiﬁcation of
he different ESAs that we  will review.
PO-mimetic  agents
his group includes the peptide molecules that act on EPO
eceptors in a similar way to endogenous EPO. The ﬁrst
PO-mimetic on the market is peginesatide (Hematide®), com-
osed of 2 peptide chains of 21 amino acids each, bound to
 polyethylene glycol group. Its half-life is estimated at 80 h
nd it may be administered as a monthly injection; there are
Table 1 – Most noteworthy events in the treatment of
renal anaemia.
1986 First publication with rH-EPO1
1990 rH-EPO approved by the EMEA
1998 “Hb normalisation” study2
2001 Darbepoetin-ɑ  introduced
2006 CREATE and CHOIR studies3,4
2007 Pegylated rH-EPO approved
2009 TREAT study5
2009 “Biosimilars” introduced
2013 First clinical trials with EPO-mimetics6,7
Table 2 – Classiﬁcation of erythropoiesis stimulating
agents.
Exogenous EPO
Epoetin and analogues
EPO-mimetic agents
Agents that stimulate endogenous EPO
Prolyl-hydroxylase inhibitors (PHIs)
GATA inhibitors
Agents with other mechanisms of action
Anti-hepcidin agents
Anti-activin agents(3):232–236 233
no differences between intravenous or subcutaneous routes.
This drug was approved by the FDA in 2012, only for use in
haemodialysis patients. As it does not require genetic tech-
nology for its manufacture, it is a less expensive product
than epoetin. Preliminary studies demonstrated other poten-
tial advantages such as the absence of immunogenicity, and
it may therefore be used in cases of pure red cell aplasia; its
greatest efﬁcacy is in patients who are more  resistant to other
ESAs.
In January 2013, 2 prospective, controlled and randomised
studies were simultaneously published for peginesatide in
patients with ACKD. The ﬁrst (EMERALD Study)  was carried out
in the U.S.A. and in Europe. It included patients on haemodial-
ysis and was compared to EPO- administered 1–3 times/week.
The main conclusion was that peginesatide, administered
once a month, resulted in haemoglobin levels equivalent to
those obtained with epoetin.6
The second study (PEARL Study)  was also developed in the
same countries and it compared the efﬁcacy of monthly pegi-
nesatide to darbepoetin every two weeks in patients with
ACKD without dialysis. The results showed a similar efﬁcacy
between the 2 drugs at the end of 52 weeks. However, sud-
den death was 7 times greater in the peginesatide group,
and the mortality rate due to unknown causes was twice
as high.7 Post-marketing data have shown serious hypersen-
sitivity reactions with several deaths,9 which lead the FDA
to withdraw its approval. Therefore, it seems reasonable to
assume that in a market as highly competitive as ESAs, the
future of peginesatide is poor.
There are other fusion proteins with EPO-mimetic proper-
ties currently in the initial study phases.
Agents  that  stimulate  endogenous
erythropoietin
Prolyl-hydroxylase  inhibitors  (PHIs)
Patients with ACKD have a relative EPO deﬁciency, and
although serum levels may be normal, they are inappropriate
for the haemoglobin concentrations they present.10 Further-
more, there may be hepatic production of EPO, which may
be stimulated during episodes of liver disease, as it was
demonstrated in patients on haemodialysis many  years ago.11
Moreover, there are EPO-producing cells that remain in the
kidneys and other tissues, with a yield sufﬁcient to main-
tain patients on haemodialysis without anaemia and no need
for ESAs. This situation is more  common in cases on a long
period of renal replacement therapy, in patients with polycys-
tic disease and in cases of liver disease due to hepatitis virus
C.12
It has been known for many  years that the inhabitants of
the Andean altiplano have adapted to the state of hypoxia
in which they live; in the same way that high altitude
affects patients on haemodialysis.13 Low oxygen pressure
induces the expression of the hypoxia-inducible factor (HIF),
a transcription factor that regulates the expression of genes
involved in erythropoiesis in response to changes in partial
oxygen pressure. It is a heterodimeric protein with 2 compo-
nents: hypoxia-sensitive HIF- and HIF-, which is an inactive
 0 1 6;3 6(3):232–236
Table 3 – Prolyl-hydroxylase inhibitors (PHIs).
PHI Pharmaceutical company Name
AKB6548 Akebia Vadadustat
GSK1278863 GSK Daprodustat234  n e f r o l o g i a. 2
component of the same molecule. The former has 3 sub-
units, which are called HIF-1,  HIF-2 and HIF-3. HIF-1 is
involved in the synthesis of EPO in embryonic states, losing
its relevance after birth. It is also involved in processes of
angiogenesis, mediated by VEGF, as well as in the anaerobic
metabolism of glucose. Recently, it has been observed that this
factor is also capable of contributing to the growth of renal
cysts.14
HIF-2  is the most important subunit and is responsible
for the changes in height and the genetic changes in the pop-
ulation that lives with these conditions. It is expressed in a
large number of cells in the body, including the endothelial
cells, hepatocytes, cardiomyocytes, glial cells, pneumocytes
and renal peritubular interstitial cells. It is responsible for
controlling EPO synthesis in adults and iron metabolism.
Experimentally, it is known that HIF-2 inactivation followed
by phlebotomy produces anaemia that cannot be recovered
from, despite normal renal function, which gives an idea of
how relevant a role it plays. For these reasons, HIF-2 becomes
an important objective for pharmacological treatment. HIF-3
is the least important subunit and seems to play an inhibitory
role.
In situations of normoxia, the participation of HIF-2 is
not necessary, and it is therefore inactivated by hydroxylation
through a proteosomal degradation process induced by prolyl-
hydroxylase (PH). At least three PH subtypes are known, called
PHD1, PHD2 and PHD3. In contrast, in situations of hypoxia,
where an increase in the number of RBCs is needed to improve
oxygen transport, HIF-2 stabilisation is produced by inhibi-
tion of the PH family. Therefore, HIF-2 becomes the main
regulator of hypoxia-induced erythropoiesis.15
Currently, a family of drugs that act as PH inhibitors (PHIs)
is being developed for clinical use. These new molecules
are capable of increasing erythropoiesis by 2 mechanisms:
ﬁrst by stabilising HIF-2 levels, which likewise stimulates
the synthesis of renal and hepatic EPO; second, through an
improvement in iron metabolism, blocking the effect of hep-
cidin. Therefore, PHIs act physiologically, using the same
mechanisms of action the body uses to adapt to less oxygen
pressure in high altitudes.16
Hepcidin, synthesised by the liver, plays an important role
in anaemia associated with inﬂammation, as it contributes
to decreasing iron bioavailability. It acts through ferroportin
degradation, which is a protein that acts as the principle
exporter of iron from all cells. It must be recalled that iron from
food is absorbed in the duodenum and subsequently passes
through blood circulation, where it is bound to transferrin.
From there, it is deposited in the liver cells and the reticu-
loendothelial system. Subsequently, in those cases in which
erythropoiesis needs to be activated, it will again enter the cir-
culation and be incorporated into the bone marrow. Therefore,
the absence of ferroportin induced by hepcidin prevents iron
from exiting the cells, which gives rise to iron sequestration in
duodenal enterocytes, hepatocytes and macrophages. Physio-
logically, hepcidin inhibition occurs in cases of anaemia, iron
deﬁciency, hypoxia (induced by HIF-2)  or due to genetic alter-
ations, such as in the case of haemochromatosis. In contrast,
hepcidin stimulation mainly occurs in cases of inﬂammation,
which contributes to the development of anaemia in these
cases.BAY 85-3934 Bayer Molidustat
FG4592 FibroGen Roxadustat
Preliminary phase 1 data have already shown the increase
in haemoglobin after treatment with FG-2216 in 12 patients
on haemodialysis and in 6 healthy controls.16 Table 3 includes
some of the PHIs recently evaluated in phase 2 clinical stud-
ies. The initial results from clinical trials have now become
available. Thus, experimentally, Molidustat is capable of stim-
ulating EPO and reticulocyte production, without increasing
blood pressure. Its effect is dose-dependent and it is admin-
istered by oral route. A daily dose of 2.5 mg/kg obtains an
effect equivalent to the administration of 100 IU/kg epoetin.17
Roxadustat was compared to placebo in a controlled and
randomised study. It was observed that a dose of 1 mg/kg
administered 2 times a week obtains a similar response on
days 1 and 29, and on both days peak plasma levels of endoge-
nous EPO were reached around 8 h after administration. The
effect on haemoglobin levels is also dose-dependent, with
optimal doses at 1.5 mg/kg. No advantages were found at
greater doses, and administration 3 times a week is preferable
to 2. In contrast, there is a signiﬁcantly greater reduction of
hepcidin levels if it is administered in doses of 2 mg/kg 3 times
per week.18 Similar results have recently been described with
Daprodustat in stage 3–5 ACKD patients regarding the increase
of haemoglobin and reticulocytes number, as well as in the
decrease of hepcidin.19 Roxadustat maintain haemoglobin
levels in patients on haemodialysis previously treated with
epoetin, and also decrease hepcidin levels.20
Therefore, PHIs constitute a new therapeutic group for the
treatment of renal anaemia with a series of advantages such
as the capacity to increase haemoglobin levels through HIF
stabilisation, thereby preventing ﬂuctuations. They can be
administered orally, enable improvement of iron mobilisation
and present a good safety proﬁle. As such, this may be a good
alternative in the future for the management of anaemia in
patients with ACKD, especially if the price is competitive as
compared to ESAs, which require recombinant engineering
processes for their manufacture. Nevertheless, more  long-
terms studies are needed to ensure that the potential effect
of HIF on angiogenesis does not present adverse effects.
GATA  inhibitors
Erythropoiesis control by HIF-2 is negatively regulated by
GATA, which is a transcription factor that inhibits EPO expres-
sion in the liver and kidneys. The main stimuli of this system
are some of the known proinﬂammatory cytokines, such as
IL-1, IL-6 or TNF (Fig. 1). There are 4 subtypes of GATA and it
seems that GATA-2 is the one that acts most potently on the
regulation EPO synthesis. Thus, just as drugs that stabilise HIF-
2 cause an increase in EPO synthesis, drugs that are capable
of blocking the GATA system can act in a similar way.
Currently, at least 2 speciﬁc GATA inhibitors are known.
Animal studies have shown that K7174, which suppresses
n e f r o l o g i a. 2 0 1 6;3  6
Hypoxia
HIF α2 GATA
GATA1
GATA2
GATA3
GATA4
PHI
IL-1 β
TNF-α
Liver and kidney
EPO
K11706
–+ –
t
t
c
o
a
u
b
o
p
a
h
A
A
I
b
d
m
a
s
h
b
f
n
i
A
A
d
i
i
b
a
i
g
I
S
o
r
Okamoto DM, et al. The effects of normal as compared withFig. 1 – Mechanism of action of GATA inhibitors.
he activity of GATA-1, -2 and -3, is capable of increasing
he synthesis of EPO previously inhibited by inﬂammatory
ytokines.21 K11706 is a much more  potent inhibitory factor
f GATA-2 and -3. In vitro experience has shown that its oral
dministration reverses the decrease in haemoglobin, retic-
locytes and colony forming units-erythroid (CFU-E) induced
y cytokines such as IL-1, or TNF-.22 Therefore, this group
f inhibitors may improve inﬂammation-induced erythro-
oiesis. Nevertheless, more  advanced-phase clinical studies
re needed to be able to show that they may have a role in
uman clinical practice.
gents  with  other  mechanisms  of  action
nti-hepcidin  agents
n addition to the inhibitory effect of hepcidin produced
y PHIs that was described above, a speciﬁc anti-hepcidin
rug has recently been developed. It was initially tested in
onkeys,23 but the ﬁrst publication in humans is now avail-
ble. This drug, known as Lexaptepid, is capable of increasing
erum iron levels and transferrin saturation in subjects who
ave previously developed an increase in hepcidin induced
y endotoxaemia. The treatment was well tolerated.24 There-
ore, treatment with anti-hepcidin drugs represents another
ew path for the management of anaemia associated with
nﬂammation.
nti-activin  agents
ctivin is a protein formed by 2 similar monomers bound by
isulphide bonds, which belongs to the TGF- superfamily. It
s mainly produced in the ovarian follicles and gonads, and
ts most important function is to regulate the menstrual cycle
y controlling FSH secretion. It also controls spermatogenesis
nd participates in healing processes and in the regulation of
nsulin secretion. In the bones, it acts as an inhibitor of bone
rowth by stimulating osteoclasts and inhibiting osteoblasts.
t has 2 types of receptors, type I and type II.Recently, an activin receptor type IIA antagonist called
otatercept was developed. In a phase 1 trial for the treatment
f osteoporosis in postmenopausal women it demonstrated(3):232–236 235
an improvement in bone formation markers and a decrease
in bone resorption, but as a side effect there was an increase
in haemoglobin levels and in reticulocyte count.25 Following
these ﬁndings, a large number of clinical trials have been
started for the treatment of anaemia associated with neoplas-
tic processes, metastasis or ACKD.
Preliminary (unpublished) data have shown in a small sam-
ple of patients on haemodialysis that Sotatercept produces a
dose-dependent improvement in haemoglobin levels; the best
response is attained with 0.7 mg/kg. An added effect was bone
formation stimulation, with an improvement in structure
and density, assessed by quantitative computed tomography,
together with an improvement in progression of vascular
calciﬁcation assessed by the Agatston score. These ﬁndings
make Sotatercept a promising molecule with the capacity to
favourably treat the standard complications of ACKD patients,
such as anaemia, vascular calciﬁcation and bone alterations.
In sum, new molecules have been developed with the
capacity to stimulate erythropoiesis by mechanisms different
to current ESAs. Some of them can be administered orally and
they have shown good tolerance to date. In addition to the
possibility of reducing treatment costs, these molecules mark
the start of a new encouraging era of anaemia management
in patients with ACKD.
Key  concepts
• New drugs for the treatment of renal anaemia, currently
in advanced clinical trials, are showing very encouraging
results for the coming years.
• PHIs stimulate erythropoiesis through HIF  stabilisation and
hepcidin inhibition.
• Activin inhibitors such as Sotatercept may act by improv-
ing anaemia, delaying vascular calciﬁcation and improving
bone structure and density.
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